Lighting the Way for Calgary: 24/7 Electric is Honored with 2025 ThreeBestRated® Award for Excellence in Service
CALGARY, ALBERTA, CANADA, June 26, 2025 / EINPresswire.com / -- Everyone has been there! When the power goes out or that light fixture starts making strange noises, this can be a headache for homeowners and businesses. Since our day-to-day life counts highly on electricity, even a small interruption can be daunting. What if a team with integrity, accountability and commitment comes to the rescue?
24/7 Electric, Inc. is doing such a job in Calgary. The team is not just another electrician, but a team with a deep commitment to listen to and meet Clargaian's growing electrical needs by exceeding their expectations. Since its inception in 2010, the team has been demonstrating exceptional professionalism and business acumen that has earned them the Award of Excellence from ThreeBestRated®.
'We have always welcomed third-party review and feedback so that we can be the best for the communities we serve,' said Stacy Walton. 'Being rated the best with the top companies in Calgary sets a standard that we aim to always be a part of.'
Why Calgary Chooses 24/7 Electric?
24/7 Electric, Inc. is a BBB accredited and Red Seal Journeyman certified electrical team. All of their electricians are extensively trained on product-specific installations and educated in safety-first practices, such as electrical shock and slips, arc flash, trips and falls. They are licensed, background-checked and continuously trained to keep up with the evolving standards in the industry. This ensures safety and peace of mind for Calgary homeowners.
Besides these credentials, what truly sets them apart is their core objective: honesty, integrity and transparency. They strive to change the perspective of homeowners about hiring electricians in their homes. From the moment they receive a call from their clients to finish the job, they work hard to gain the customer's trust and be accountable for the job they complete. 'We believe that trust is earned, integrity is gained and accountability needs to be proven.'
24/7 Electric has another compelling reason why they are a trusted partner for Calgarians. They have won several awards to showcase their excellence and dedication. 24/7 Electric team is an…
>> 2-time winner of the Business Ethics Award,
>> 7-time winner of the ThreeBestRated® Award,
>> Recipient of 'Best of the Best' Electrical Business in Alberta,
>> Recipient of 'Giving Back' Award
The team's commitment to excellence and relentless pursuit of customer satisfaction have been instrumental in achieving these accolades and recognitions. Top of all, they have garnered over 500 five-star reviews across multiple platforms. All of them tell the story of their happy clients that reflect their core values.
Always On, Always There
True to their name, 24/7 Electric offers round-the-clock support, schedules appointments for their customers' convenience with transparent pricing. Whether it is a planned upgrade or an unexpected emergency, their team is ready to respond with a smile.
More than just fixing problems, 24/7 Electric makes them stand out by educating their clients on the major systems in homes. 'A majority of our customers are new home buyers and are not well versed in the mechanics. We focus on educating our customers with the work being completed, why, and what the cost will be upfront, prior to beginning. We break down complex problems with step-by-step explanations to manage expectations on how the repair or upgrade will go,' said Stacy. For more information or to contact them, visit 247electriccalgary.com.
Stacy Walton
24/7 Electric
+1 587-315-1361
[email protected]
Visit us on social media:
YouTube
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Barrick Mining reports second-quarter profit up from year ago
TORONTO — Barrick Mining Corp. reported its second-quarter profit rose compared with a year ago, helped by a higher price for gold. The mining company, which keeps its books in U.S. dollars, says it earned US$811 million or 47 cents US per diluted share for the quarter ended June 30, up from US$370 million or 21 cents US per diluted share a year earlier. On an adjusted basis, Barrick says it earned 47 cents US per share in its latest quarter, up from an adjusted profit of 32 cents US in the same quarter last year. Revenue for the quarter totalled US$3.68 billion, up from US$3.16 billion a year earlier. Gold production in the quarter totalled 797,000 ounces, down from 948,000 a year ago, while Barrick's realized gold price amounted to US$3,295 per ounce, up from US$2,344 a year ago. Copper production totalled 59,000 tonnes, up from 43,000 tonnes a year ago, while the company's realized copper price was US$4.36 per pound, down from US$4.53 in the same quarter last year. This report by The Canadian Press was first published Aug. 11, 2025. Companies in this story: (TSX:ABX) The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Northisle Copper and Gold completes brokered and non-brokered private placements
Northisle Copper and Gold has successfully closed its brokered and non-brokered private placements, securing a total of C$39.5m ($28.7m) in gross proceeds. The financing includes a significant investment from Wheaton Precious Metals, marking a robust phase of capital inflow for the mining company. The brokered offering generated approximately C$34.5m, comprising around 9.33 million common shares (flow-through or CFT Shares) at C$1.6065 each and nearly 18.57 million common shares (Non-CFT Shares) at C$1.05 each. This includes an over-allotment option, resulting in an additional 4.28 million shares. Paradigm Capital led the syndicate of agents, which also included First Nations Financial Markets, Red Cloud Securities, Ventum Financial and Raymond James. The agents received a commission of approximately C$1.87m, calculated as 6% of the gross proceeds, except for a reduced 2% commission on subscriptions from a president's list provided by Northisle. The brokered shares, offered to Canadian residents excluding Quebec, are not subject to a statutory hold period, except for the TSX Venture Exchange's four-month rule. Some shares were also issued in the US under exemptions from the US Securities Act's registration requirements. The non-brokered offering, comprising around 4.76 million common shares at C$1.05 each, raised approximately C$5m. These shares are subject to a four-month-plus-one-day hold period under Canadian securities laws. The proceeds from the CFT Shares will finance eligible Canadian exploration expenses at the North Island Project. The funds from the Non-FT Shares and the non-brokered offering will support exploration, project development and general corporate activities. In relation to the non-brokered offering, Wheaton Precious Metals has entered into an agreement with Northisle, providing Wheaton with a right of first refusal on precious metal streams or royalties on selected claims from the North Island Project. This includes a 1km area of interest surrounding these claims, in exchange for C$10,000. "Northisle Copper and Gold completes brokered and non-brokered private placements" was originally created and published by Mining Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ('Quantum BioPharma' or the 'Company'), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral drug formulation of Lucid-MS. The oral formulation of Lucid-MS will serve as the drug product for the Company's Phase 2 clinical trial, which will test the efficacy on humans of Lucid-MS as a possible treatment for people to gain back mobility lost with multiple sclerosis (MS). To date numerous animal models over the past decade showed Lucid-MS helped those animals regain their ability to walk. Videos can be seen at Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of MS. It is a patented New Chemical Entity (NCE) that has been shown in preclinical models to prevent demyelination, which is a hallmark of MS and other neurogenerative diseases and is characterized by damage to the myelin sheath surrounding nerve fibers. 'We are pleased to announce that we have signed this agreement with a leading CDMO to develop and manufacture an oral formulation of Lucid-MS. This marks an important step in the clinical development of Lucid-MS as we prepare the Investigational New Drug (IND) application with the FDA and prepare for our upcoming Phase 2 trial of Lucid-21-302 in MS,' said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma. About Quantum BioPharma Ltd. Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information on Quantum BioPharma, please visit Forward-Looking Information This press release contains certain 'forward-looking statements' within the meaning of applicable Canadian securities law. Forward-looking statements are frequently characterized by words such as 'plan,' 'continue,' 'expect,' 'project,' 'intend,' 'believe,' 'anticipate,' 'estimate,' 'may,' 'will,' 'potential,' 'proposed' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. Forward-looking statements include the Company's belief that its investment in GameStop represents a strategic opportunity and its expectation of a potential increase in GameStop's stock price. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors, including the risk that the GameStop stock price may not increase as anticipated, that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at and on the EDGAR section of the United States Securities and Exchange Commission's website at for a more complete discussion of such risk factors and their potential effects. Contacts: Quantum BioPharma Ltd. Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board Email: Zsaeed@ (833) 571-1811 Investor Relations Investor Relations: IR@ Inquiries: info@ in to access your portfolio
